A Phase 1/2, open-label, single-arm, dose-escalation and dose-expansion study of the safety, tolerability, pharmacokinetic, and antitumor activity of E-602 as a single agent and in combination with Cemiplimab in patients with advanced cancers
Study of E-602 Alone or in Combination with Libtayo (Cemiplimab) in Patients with Advanced Cancer
Sponsor: Palleon Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAU1677
U.S. Govt. ID: NCT05259696
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to test the safety of the study drug, E-602, at different dose levels both alone (monotherapy) and in combination with Cemiplimab (also known as Libtayo). Cemiplimab is FDA-approved for the treatment of some cancers, but not all of the cancers in this study. E-602 has not been approved by the United States Food and Drug Administration (FDA). This study is the first time that E-602 will be administered to participants. The study will also inform on what effects, both good and bad, E-602 alone and in combination with Cemiplimab have on participants with advanced cancer. Cancers include: breast cancer, colon and rectal cancer, esophageal cancer, head and neck/oral cancer, lung cancer, melanoma, pancreatic cancer, and ovarian cancer.
This study is closed
Brian Henick, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with advanced cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator